SCHEMBL5098523

SCHEMBL5098523

COc1ccc(C(N)=O)c(N2CCCCC2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.56
CDC7 O00311 2/20 0.53
CDK9 P50750 1/20 0.53
HTT P42858 2/20 0.52
MAPT P10636 5/20 0.50
KDM4E B2RXH2 3/20 0.50
HSD17B10 Q99714 3/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
GFER P55789 2/20 0.50
THRB P10828 1/20 0.50
ALOX15 P16050 1/20 0.50
YWHAG P61981 1/20 0.50
ALDH1A1 P00352 4/20 0.49
GAA P10253 2/20 0.49
ROCK2 O75116 1/20 0.49
MAP4K4 O95819 1/20 0.49
CDK2 P24941 1/20 0.49
GSK3B P49841 1/20 0.49
CLK4 Q9HAZ1 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6646083 0.87 KEAP1 (0.49) HTTMAPTKDM4EHSD17B10MEN1
SCHEMBL5104807 0.85 NPC1 (0.52) NPC1CDC7CDK9HTTMAPT
SCHEMBL3538450 0.78 NPC1 (0.63) NPC1CDC7CDK9HTTMAPT
SCHEMBL3911050 0.78 CPS1 (0.60) NPC1KDM4EHSD17B10MEN1KMT2A
SCHEMBL11161766 0.78 SMN1; SMN2 (0.56) HTTMAPTKDM4EMEN1KMT2A
SCHEMBL3085532 0.77 NPC1 (0.61) NPC1CDC7CDK9HTTMAPT
SCHEMBL3086459 0.77 NPC1 (0.61) NPC1CDC7CDK9HTTMAPT
SCHEMBL5097993 0.77 NPC1 (0.56) NPC1CDC7CDK9HTTMAPT
SCHEMBL5092055 0.76 ALDH1A1 (0.59) NPC1HTTMAPTKDM4EHSD17B10
SCHEMBL1812327 0.76 RAB9A (0.52) NPC1MAPTKDM4EHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1812425-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-01 EP claimed
WO-2006047479-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO claimed
US-20050131022-A1 C-fms kinase inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2005-06-16 US claimed
US-7427683-B2 c-fms kinase inhibitors ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2008-09-23 US disclosed
EP-1812425-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-01 EP disclosed
WO-2006047479-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed
US-20050131022-A1 C-fms kinase inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131022-A1 C-fms kinase inhibitors FLT3, FES, FGR NPC1 4199/4885CDC7 285/4885CDK9 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.